Basal Cell Carcinoma (Regeneron Study)

Study Description

Brief Summary

The primary objective is to characterize the safety and tolerability of cemiplimab injected intralesionally in patients with Cutaneous Squamous Cell Carcinoma (CSCC) or Basal Cell Carcinoma (BCC)

The secondary objectives of this study are:

To describe the objective response rate (ORR) in CSCC or BCC index lesions following intralesional injections of cemiplimab in patients with CSCC or BCC, according to modified World Health Organization (WHO) criteria
To describe the pathologic complete response (CR) rate in CSCC or BCC index lesions following intralesional injections of cemiplimab in patients with CSCC or BCC
To describe the major pathologic response rate in CSCC or BCC index lesions following intralesional injections of cemiplimab in patients with CSCC or BCC
To evaluate systemic exposure of cemiplimab following intralesional injections of cemiplimab in patients with CSCC or BCC
To assess the immunogenicity of cemiplimab in patients with CSCC or BCC
To establish a recommended dose of intralesional cemiplimab for further study in patients with CSCC or BCC

Condition or Disease

Cutaneous Squamous Cell Carcinoma

Basal Cell Carcinoma

Study Design

Study Type:	Interventional (Clinical Trial)
Estimated Enrollment:	61 participants
Allocation:	N/A
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	A Phase 1 Study of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, for Patients With Cutaneous Squamous Cell Carcinoma (CSCC) or Basal Cell Carcinoma (BCC)
Actual Study Start Date:	April 11, 2019
Estimated Primary Completion Date:	October 26, 2023
Estimated Study Completion Date:	January 11, 2024

Eligibility Criteria

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Inclusion Criteria:

Dose Escalation: History of recurrent resectable CSCC that satisfies conditions as defined in the protocol
Patient must have measurable disease in the index lesion, as defined by modified WHO criteria. Measurable disease is defined as at least one lesion that is at least 1 cm in both of the longest perpendicular diameters.
Eastern Cooperative Oncology Group (ECOG) performance status ≤1

Exclusion Criteria:

Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related adverse events (irAEs)
Prior treatment with an agent that blocks the programmed cell death
1 (PD-1)/ programmed cell death 1 ligand (PD-L1) pathway.
Prior treatment with other systemic immune modulating agent as defined in the protocol
M1 or N1, N2 (a, b, or c), or N3 CSCC or BCC. Patients with history of metastatic CSCC (distant or nodal), or metastatic BCC (distant or nodal) are excluded unless the disease-free interval is at least 3 years
Concurrent malignancies, other than those with negligible risk of metastasis or death. Patients with hematologic malignancies, including chronic lymphocytic leukemia (CLL), are excluded.
Patients with a history of solid organ transplant
Has received a COVID-19 vaccination (initial series and booster) within 1 week of planned start of study medication

Note: Other protocol defined Inclusion/Exclusion criteria apply.

ADDITIONAL DETAILS

Application for Clinical Trials

Name(Required)

First Name Last Name

Phone(Required)

Email(Required)

Birthday(Required)

Select a State(Required)

Select a Condition (Arizona)(Required)

Select a Condition (Kansas)(Required)

Select a Condition (Maryland)(Required)

Select a Condition (Missouri)(Required)

Select a Condition (Texas)(Required)

Select a Clinical Trial: Actinic Keratosis (Arizona)(Required)

Select a Clinical Trial: Alopecia Areata (Maryland)(Required)

Select a Clinical Trial: Atopic Dermatitis (Arizona)(Required)

Select a Clinical Trial: Atopic Dermatitis (Texas)(Required)

Select a Clinical Trial: Atopic Dermatitis (Maryland)(Required)

Select a Clinical Trial: Atopic Dermatitis (Missouri)(Required)

Select a Clinical Trial: Atopic Dermatitis (Kansas)(Required)

Select a Clinical Trial: Bullous Pemphigoid (Arizona)(Required)

Select a Clinical Trial: Hidradenitis Suppurativa (Arizona)(Required)

Select a Clinical Trial: Prurigo Nodularis (Arizona)(Required)

Select a Clinical Trial: Prurigo Nodularis (Maryland)(Required)

Select a Clinical Trial: Psoriasis (Arizona)(Required)

Select a Clinical Trial: Rosacea (Arizona)(Required)

Select a Clinical Trial: Psoriasis (Texas)(Required)

Select a Clinical Trial: Psoriasis (Maryland)(Required)

Select a Clinical Trial: Psoriasis (Missouri)(Required)

Select a Clinical Trial: Psoriasis (Kansas)(Required)

Select a Clinical Trial: Skincare (Arizona)(Required)

Select a Clinical Trial: Skin Cancer (Arizona)(Required)

Select a Clinical Trial: Skin Cancer (Missouri)(Required)

Select a Clinical Trial: Skin Cancer (Maryland)(Required)

Select a Clinical Trial: Vitiligo (Texas)(Required)

Select a Clinical Trial: Vitiligo (Missouri)(Required)

Select a Clinical Trial: Vitiligo (Kansas)(Required)

How did you hear about us?(Required)

Message(Required)

CAPTCHA

Name

This field is for validation purposes and should be left unchanged.

Menu

Study Description

Brief Summary

Condition or Disease

Study Design

Eligibility Criteria

Inclusion Criteria:

Application for Clinical Trials

ACTIVE TRIALS

LOCATIONS

NAVIGATION

SOLUTIONS